Magnesium Sulfate Demo (Magnesium Sulfate Heptahydrate)

Magnesium sulfate supplies magnesium ions that act as a calcium antagonist, blocking voltage‑dependent calcium channels and reducing intracellular calcium. This produces smooth‑muscle relaxation, vasodilation, and stabilisation of neuronal and cardiac membranes. In the brain it inhibits NMDA receptors, decreasing excitatory signalling, while in the heart it prolongs the refractory period to prevent abnormal rhythms.

The dosage of Magnesium Sulfate Demo is determined by the prescribing clinician based on the specific indication, patient weight, renal function and clinical response. The prescriber sets the infusion rate and total amount required; no standard dose is provided here.

Magnesium sulfate is commonly used in pregnancy for the treatment of severe preeclampsia and eclampsia, and its safety profile in this setting is well established. However, use during pregnancy or lactation should be guided by a qualified health professional who will weigh benefits against any potential risks.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and any required import documentation.

The primary alternative to magnesium sulfate for seizure prophylaxis in preeclampsia is calcium gluconate, while other anti‑arrhythmic agents such as lidocaine are used for ventricular tachyarrhythmias. Magnesium sulfate offers the advantage of simultaneous electrolyte replacement and vasodilation, but its efficacy and safety must be evaluated against the specific clinical scenario and patient characteristics.

Magnesium Sulfate Demo should be stored below 25 °C in its original packaging, protected from moisture and direct sunlight. The container must remain sealed until use, and any opened vial should be used within the time frame recommended by the manufacturer to maintain sterility.

The product is administered intravenously, typically as a controlled infusion under continuous clinical monitoring. The rate of infusion is adjusted according to the indication, patient response and serum magnesium levels, and infusion sets should be compatible with sterile solutions.

The most critical risks include hypermagnesemia leading to respiratory depression, severe hypotension, cardiac arrest, and neuromuscular blockade. Prompt recognition of symptoms such as loss of deep tendon reflexes, respiratory slowing, or profound blood pressure drops is essential, and calcium gluconate should be readily available as an antidote.

Magnesium sulfate should be avoided in patients with known hypersensitivity to magnesium salts, severe renal failure where clearance is impaired, existing heart block without a pacemaker, and in individuals with myasthenia gravis or other severe neuromuscular disorders unless closely monitored.